A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)

Egbert F. Smit; Yi-Long Wu; Radj Gervais; Caicun Zhou; Enriqueta Felip; Jifeng Feng; Salih Zeki Guclu; Mathias Hoiczyk; Elena Dorokhova; Ulrich Freudensprung; Susan Grange; Pablo Diego Perez-Moreno; Lada Mitchell; Martin Reck

doi:10.1016/j.lungcan.2016.06.019

A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)

Egbert F. Smit, Yi-Long Wu, Radj Gervais, Caicun Zhou, Enriqueta Felip, Jifeng Feng, Salih Zeki Guclu, Mathias Hoiczyk, Elena Dorokhova, Ulrich Freudensprung, Susan Grange, Pablo Diego Perez-Moreno, Lada Mitchell, Martin Reck

Pulmonary medicine

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	94-101
Journal	Lung Cancer
Volume	99
DOIs	https://doi.org/10.1016/j.lungcan.2016.06.019
Publication status	Published - Sep 2016

Access to Document

10.1016/j.lungcan.2016.06.019

Cite this

Smit, E. F., Wu, Y-L., Gervais, R., Zhou, C., Felip, E., Feng, J., Guclu, S. Z., Hoiczyk, M., Dorokhova, E., Freudensprung, U., Grange, S., Perez-Moreno, P. D., Mitchell, L., & Reck, M. (2016). A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). Lung Cancer, 99, 94-101. https://doi.org/10.1016/j.lungcan.2016.06.019

@article{fcd4d439eae14388ad4cf21670b147f0,

title = "A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)",

keywords = "Erlotinib, NSCLC, Smoking, Increased dose, Pharmacokinetics",

author = "Smit, {Egbert F.} and Yi-Long Wu and Radj Gervais and Caicun Zhou and Enriqueta Felip and Jifeng Feng and Guclu, {Salih Zeki} and Mathias Hoiczyk and Elena Dorokhova and Ulrich Freudensprung and Susan Grange and Perez-Moreno, {Pablo Diego} and Lada Mitchell and Martin Reck",

year = "2016",

month = sep,

doi = "10.1016/j.lungcan.2016.06.019",

language = "English",

volume = "99",

pages = "94--101",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

Smit, EF, Wu, Y-L, Gervais, R, Zhou, C, Felip, E, Feng, J, Guclu, SZ, Hoiczyk, M, Dorokhova, E, Freudensprung, U, Grange, S, Perez-Moreno, PD, Mitchell, L & Reck, M 2016, 'A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)', Lung Cancer, vol. 99, pp. 94-101. https://doi.org/10.1016/j.lungcan.2016.06.019

TY - JOUR

T1 - A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)

AU - Smit, Egbert F.

AU - Wu, Yi-Long

AU - Gervais, Radj

AU - Zhou, Caicun

AU - Felip, Enriqueta

AU - Feng, Jifeng

AU - Guclu, Salih Zeki

AU - Hoiczyk, Mathias

AU - Dorokhova, Elena

AU - Freudensprung, Ulrich

AU - Grange, Susan

AU - Perez-Moreno, Pablo Diego

AU - Mitchell, Lada

AU - Reck, Martin

PY - 2016/9

Y1 - 2016/9

KW - Erlotinib

KW - NSCLC

KW - Smoking

KW - Increased dose

KW - Pharmacokinetics

U2 - 10.1016/j.lungcan.2016.06.019

DO - 10.1016/j.lungcan.2016.06.019

M3 - Article

C2 - 27565921

VL - 99

SP - 94

EP - 101

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -